Publications
Cell reports. MedicineMay 2021 |
2
(
6
),
100313
DOI:
10.1016/j.xcrm.2021.100313

Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions

Shiakolas, Andrea R; Kramer, Kevin J; Wrapp, Daniel; Richardson, Simone I; Schäfer, Alexandra; Wall, Steven; Wang, Nianshuang; Janowska, Katarzyna; Pilewski, Kelsey A; Venkat, Rohit; Parks, Robert; Manamela, Nelia P; Raju, Nagarajan; Fechter, Emilee Friedman; Holt, Clinton M; Suryadevara, Naveenchandra; Chen, Rita E; Martinez, David R; Nargi, Rachel S; Sutton, Rachel E; Ledgerwood, Julie E; Graham, Barney S; Diamond, Michael S; Haynes, Barton F; Acharya, Priyamvada; Carnahan, Robert H; Crowe, James E; Baric, Ralph S; Morris, Lynn; McLellan, Jason S; Georgiev, Ivelin S
Product Used
Genes
Abstract
The continual emergence of novel coronavirus (CoV) strains, like SARS-CoV-2, highlights the critical need for broadly reactive therapeutics and vaccines against this family of viruses. From a recovered SARS-CoV donor sample, we identify and characterize a panel of six monoclonal antibodies that cross-react with CoV spike (S) proteins from the highly pathogenic SARS-CoV and SARS-CoV-2, and demonstrate a spectrum of reactivity against other CoV. Epitope mapping reveals that these antibodies recognize multiple epitopes on SARS-CoV-2 S, including the receptor binding domain, N-terminal domain, and S2 subunit. Functional characterization demonstrates that the antibodies mediate phagocytosis - and in some cases trogocytosis - but not neutralization in vitro. When tested in vivo in murine models, two of the antibodies demonstrate a reduction in hemorrhagic pathology in the lungs. The identification of cross-reactive epitopes recognized by functional antibodies expands the repertoire of targets for pan-coronavirus vaccine design strategies.
Product Used
Genes

Related Publications